Pharmacological action of FPL 55712 on canine cerebral arterial segments.
The pharmacological action of a leukotriene antagonist FPL 55712 was studied on canine cerebral arterial segments. FPL 55712 at concentrations of 10(-6)M and 10)-5)M showed dose-dependent inhibition of the constrictor responses of the artery to prostaglandin F2 alpha. The constrictor responses of the artery to either serotonin or haemoglobin were suppressed by 10(-5)M FPL 55712, while 10(-6)M FPL 55712 failed to alter the responses. The KCL-induced constriction was not affected by treatment with either 10(-6)M or 10(-5)M FPL 55712. The present results suggest that FPL 55712 has vasodilator properties other than those related to the inhibition of leukotrienes.
D000818:Animals; D002536:Cerebral Arteries / Q000187:drug effects*; D002867:Chromones / Q000494:pharmacology*; D015237:Dinoprost; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D006454:Hemoglobins; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D011189:Potassium Chloride / Q000494:pharmacology; D011460:Prostaglandins F / Q000494:pharmacology; D013189:SRS-A / Q000037:antagonists & inhibitors*; D012701:Serotonin / Q000494:pharmacology; D014661:Vasoconstriction / Q000187:drug effects*
D002867:Chromones; D006454:Hemoglobins; D011460:Prostaglandins F; D013189:SRS-A; D012701:Serotonin; D011189:Potassium Chloride; C006312:FPL 55712; D015237:Dinoprost